When was Waypoint founded?

Waypoint was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Waypoint located?

Waypoint is headquartered in New York City, United States.

Who is the current CEO of Waypoint?

Xinchen Wang of Waypoint. They have also founded 1 company.

How many employees does Waypoint have?

As of Sep 30, 2026, the latest employee count at Waypoint is 19.

Is Waypoint a funded company?

Waypoint is a funded company, having raised a total of $34.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 28, 2024.

When was the latest funding round of Waypoint?

Waypoint's latest funding was a $***** Series A round on Jun 01, 2026, with participation from 6 investors.

Where does Waypoint rank among its competitors?

Waypoint ranks 137th amongst 3398 active competitors, of which 1133 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Waypoint?

Waypoint's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Waypoint - 2026 Company Profile, Team, Funding & Competitors

Most viewed in 2019

Waypoint is a series A company based in New York City (United States), founded in 2021 by Xinchen Wang. It operates as a Digital cell therapy platform for providers. Waypoint has raised $34.5M in funding from Amplify Partners and Hummingbird Ventures. The company has 3398 active competitors, including 1133 funded and 785 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Key Metrics

Founded Year

2021

Location

New York City, United States

Stage

Series A

Total Funding

$34.5M in 2 rounds

Latest Funding Round

Series A, Jun 01, 2026, $*****

Investors

Amplify Partners & 9 more

Ranked

137^th among 3398 active competitors

Employee Count

19 as on Sep 30, 2026

Similar Companies

Senti Bio & 146 more

View Waypoint's full profile

Waypoint has raised a total funding of $34.5M over 2 rounds. Its first funding round was on Jun 28, 2024. Its latest funding round was a Series A round on Jun 01, 2026 for $*****. 6 investors participated in its latest round. Waypoint has 10 institutional investors.

Here is the list of recent funding rounds of Waypoint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2026	4898898	Series A	8352648	8797229	9898975	1518006
Jun 28, 2024	4444756	Seed	1589846	4180221	Hummingbird Ventures	Recode Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Waypoint's funding rounds and investors

The founders of Waypoint is Xinchen Wang. Xinchen Wang is the CEO of Waypoint.

Here are the details of Waypoint's key team members:

Xinchen Wang: Co-Founder & CEO of Waypoint.
Contact Info: 1 email address

View details of Waypoint's Founder profiles and Board Members

Waypoint's employee count trend

Waypoint has 19 employees as of Sep 26. Here is Waypoint's employee count trend over the years:

Uncover Waypoint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Waypoint include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Waypoint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
137th	Waypoint 2021, New York City (United States), Series A	Digital cell therapy platform for providers	$34.5M	Hummingbird Ventures, Amplify Partners & 8 others	61/100